Curiosity, cancer and circulating tumor cells: Gaining new cancer insights through CTC analyses

Feb 20, 2018 11:00 AM–12:00 PM (EST)
Duration: 1hrs
Over the last decade, circulating tumor cells (CTCs) have been extensively studied and the molecular characterization and analysis of these cells has provided important insights into cancer biology. The release of CTCs from the tumor into the blood was identified to be driven by the epithelial to mesenchymal transition (EMT) phenomenon and their survival and metastatic capacity could be correlated with a phenotype change into so-called tumor stem cells. Furthermore, the molecular characterization of CTCs provided deeper knowledge of drug resistance mechanisms, changes in the mutational profile and adaptive survival strategies in such cells.

In this webinar, we present a method for CTC enrichment and molecular characterization, which only requires standard laboratory equipment. This strategy combines immunomagnetic enrichment of CTCs using a mixture of antibodies rather than a single antibody, followed by molecular profiling of the CTCs captured.  Use of an antibody mixture directed against multiple tumor cell-associated antigens during enrichment allows the identification of tumor cells with changing antigen profiles once they develop an EMT or tumor stem cell phenotype.  These cells would otherwise be missed during the enrichment step. In subsequent downstream molecular profiling, several tumor-related genes are then analyzed in parallel to reconcile any changes in the CTC metabolism due to their reaction to the blood environment, drug influence or even general tumor variability.

Constanze Kindler, Ph.D.

Constanze Kindler

Dr. Constanze Kindler joined QIAGEN in Hilden, Germany in 1993, where she held various positions in Sales and Global Marketing. She received her Ph.D in Molecular Biology from the University of Münster in 1993. Currently Dr. Kindler is Senior Global Product Manager Sample Technologies with a focus on liquid biopsy applications.